BioMarin Pharmaceuticals Inc. presented 1Q 2010 earnings, with Naglazyme (Galsulfase) to treat Mucopolysaccharidosis VI, followed by
Kuvan° (Sapropterin) indicated for Phenylketonuria .

QTR: Elan Corp. presented 1Q 2010 earnings, with
multiple sclerosis drug Tysabri (Natalizumab) followed by antibiotic Azactam (Aztreonam) and sclerosis multiple walker improver drug Ampyra (Dalfampridine), 2009 and 2008 comparative charts.

Endo Pharma presented 1Q 2010 earnings withLidoderm(Lidocaine 5%) to treat post-herpetic neuralgia, followed by Opana(Oxymorphone) for the relief of moderate to severe pain and Percocet(Oxycodone + Acetaminophen)also to treat moderate to moderately severe pain.

Below is a listing of Mitsubishi Tanabe Pharma 1Q 2010 Top Five best selling drugs.

Mitsubishi Tanabe Pharma 1Q 2010 best selling drugs with Remicade (Infliximab) to treat Rheumatoid Arthritis, followed by strokes prevention drug Radicut (Edavarone) and Anplag (Sarpogrelate), Arterial Thrombosis/ Diabetes/Raynauds/Buerger. 2008 and 2009 comparative charts.

Actelion Ltd. presented 1Q 2010 earnings, with Tracleer (Bosentan) followed by Ventavis (Iloprost), both to treat Pulmonary Arterial Hypertension. 2008 and 2009 comparative charts.

Genzyme Corp. presented 1Q 2010 earnings, with lead Gaucher Type 1 drug Cerezyme (Imiglucerase) followed by renal hyperphesfatemia drug Renagel/Renvela (Sevelamer) and Pompe Disease drug Myozyme (Alglucosidase)

Gilead Sciences Inc. presented 1Q 2010 earnings, with HIV drug Truvada ((Emtricitabine + Tenofovir) as blockbuster drug, followed by combined HIV Atripla (Efavirenz + Emtricitabine + Tenofovir) and Viread (Emtricitabine). 2008 and 2009 comparative chart.

Biogen Idec presented 1Q 2010 earnings, best selling drug multiple sclerosis drug, Avonex (Interferon Beta 1A) followed by Tysabri (Natalizumab)

Amylin Pharmaceuticals Inc. presented sales for 1Q 2010, leading drug is Diabetes II type, Byetla (Exenatide) followed by Type I and II Diabetic Drug, Symlin (Pramlintide).

Swiss biotech Actelion posted its third-quarter earnings in 2008, revealing artery lung hypertension drug Tracleer as its top seller. Below is the list of the company´s top selling drugs in the first nine months of the year.

Biotech CV Therapeutics posted its third-quarterly 2008 earnings for Ranexa, its only marketed drug. Below, Ranexa sales in the first nine months of this year.

Cephalon Inc reported a third-quarter profit that missed analyst expectations, but its new cancer drug Treanda continued an impressive launch, and raised its full-year earnings forecast.

Cephalon Inc posted its third-quarter earnings, with insomnia drug Provigil taking top place. Below is a list of the biotech company’s sales for the first nine months of the year.

Massachusetts-based Sepracor Inc posted its third-quarter earnings for 2008, with insomnia drug Lunesta taking top place. The list of drugs and their sales for the first nine months of this year can be seen below.

Sepracor Inc posted a sharp decline in third-quarter profit, as lower reimbursement rates from Medicare hurt sales of its asthma drug Xopenex.

Celgene has presented its Q3 2008 financial results, featuring the multiple myeloma drugs Revlimid and Thalomid as the company´s key revenue drivers. First nine months results.

U.S biotech Celgene Corp posted third-quarter profit that more than tripled on a 69 percent rise in revenues. Most of the company´s revenue growth came from its top-selling bone-marrow cancer drug Revlimid. Further Details.

Biotech giant Genzyme posted its 3Q 2008 financial results. Genzyme´s blockbuster Cerezyme and its phosphorus drug Renagel lead tops list of its most widely sold drugs. Full information of first nine months results 2008

California-based biotech Amgen Inc posted its third-quarter 2008 earnings, with Enbrel (rheumatoid arthritis & others) taking top-place. Below a full list of the company´s best selling drugs in the first nine months of this year.